Earn rewards for your opinion on lab products.

Get exclusive insights into life science trends.

Stay up to date on research news.

Researchers create artificial nanopores capable of detecting DNA
November 24, 2021 -- Scientists have designed bottom-up peptides that can form artificial nanopores to identify and enable single molecule-sorting of genetic material in a lipid membrane, according to new research published in Nature Nanotechnology on November 22. Read More
Stem cell model reveals gene expression during development of hypothalamus
November 23, 2021 -- Researchers created an in vitro stem cell model of the hypothalamus to study its development over different stages. In doing so, they identified several genes involved with bodily functions associated with the hypothalamus, including disorders related to sleep and reproduction, according to research published November 19 in Nature Communications. Read More
Asgard Therapeutics raises seed funding for novel in vivo cancer immunotherapy
November 22, 2021 -- Asgard Therapeutics, a private biotech startup based in Lund, Sweden, has raised 6 million euros (about $6.8 million) in seed financing, co-led by Novo Holdings, a global life science investor based in Hellerup, Denmark. Read More
Technology upgrades needed to address future pandemics, GAO report says
November 19, 2021 -- Vaccine R&D and manufacturing face many challenges despite the success of COVID-19 vaccines. This is according to a new U.S. Government Accountability Office (GAO) report. Read More
Myxoma virus enters as an exciting preclinical cancer immunotherapy platform
November 18, 2021 -- A preclinical oncolytic viral vector platform under development was of interest at the recent Society for Immunotherapy of Cancer's 2021 annual meeting. OncoMyx Therapeutics' Chief Scientific Officer Leslie Sharp, PhD, spoke with ScienceBoard at the meeting. Read More
5 takeaways from SITC 2021
November 17, 2021 -- WASHINGTON, DC - The Society for Immunotherapy of Cancer's (SITC) 2021 annual meeting November 10-14 was a successful gathering of research and clinical experts focused on the development of innovative cancer treatments. The ScienceBoard team was live onsite at the event. Editor in Chief Samantha Black, PhD, shared five takeaways from the meeting. Read More
Innovation and safety remain key amid shifting pandemic-impacted clinical trial protocols
November 16, 2021 -- WASHINGTON, DC - During the pandemic, clinical trial execution for cancer therapies has been challenging, said Dr. Samit Hirawat, chief medical officer at Bristol Myers Squibb, at the Society for Immunotherapy of Cancer's 2021 annual meeting. Despite the challenges presented by the pandemic, Hirawat noted that stakeholders held patient safety and innovation as key priorities. Hirawat spoke with ScienceBoard onsite at the meeting. Read More
Why one industry veteran launched a new cancer immunotherapy company
November 16, 2021 -- WASHINGTON, DC - Raphaël Ognar spoke with ScienceBoard onsite at the Society for Immunotherapy of Cancer's 2021 annual meeting about the launch of NKILT Therapeutics. Read More
Where is the immunotherapy field headed after COVID-19?
November 15, 2021 -- WASHINGTON, DC - Best known for his contributions to the Moderna COVID-19 vaccine, former Moderna chief medical officer, Dr. Tal Zaks, PhD, chaired a session on RNA vaccines at the Society for Immunotherapy of Cancer's (SITC) 2021 annual meeting. Zaks shared his perspectives and hopeful outlook with ScienceBoard at the meeting. Read More
Is the accelerated approval process working for cancer immunotherapies?
November 15, 2021 -- WASHINGTON, DC - Leveraging years of experience, Dr. Alessandra Cesano, PhD, who serves on the board of directors of the Society for Immunotherapy of Cancer (SITC), chaired a panel discussion on the accelerated approval process for cancer immunotherapies at the organization’s 2021 annual meeting. Cesano spoke with ScienceBoard at the meeting. Read More
Researchers dig into how myeloid cells contribute to killing cancer
November 15, 2021 -- WASHINGTON, DC - Dr. Miriam Merad, PhD, director of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai is working on characterizing myeloid cells in cancer patients. Merad spoke with ScienceBoard at the Society for Immunotherapy of Cancer's 2021 annual meeting. Read More
New neoadjuvant platform helps inform combo immunotherapy selection for cancers
November 13, 2021 -- WASHINGTON, DC - In order to address some of the major challenges facing the immuno-oncology field, Dr. Tom Marron, PhD, has developed a platform to help researchers decide which drugs or combination of drugs to advance toward late-stage clinical trials. Marron spoke with ScienceBoard Editor in Chief, Samantha Black, PhD, onsite at the Society for Immunotherapy of Cancer's 2021 annual meeting. Read More
Illumina for Startups pushes boundaries of genomics by supporting early-stage companies
November 12, 2021 -- Most scientists are familiar with the genomics giant Illumina, which is known for its DNA sequencing technologies. However, Illumina has an accelerator program to support early-stage startups called Illumina for Startups. ScienceBoard.net recently spoke with Amanda Cashin, PhD, who leads Illumina's accelerator programs in the U.S. and internationally. Read More
$2.7B oncology cell and gene therapy market projected for 2021
November 11, 2021 -- The global market for oncology cell and gene therapies reached $1.6 million in 2020 and is expected to reach $2.744 billion in 2021, according to a recent article in Cell and Gene Therapy Business Outlook, a sister subscription-based publication of ScienceBoard.net. Read More
Can cell therapies treat cardiovascular disease?
November 10, 2021 -- While the development of cell therapies today is largely focused on oncology indications, some companies, including Athersys, envision a future where these therapies could treat other diseases and conditions, such as cardiovascular disease. B.J. Lehmann, interim CEO of Athersys, spoke with ScienceBoard.net about a recent panel that he participated in at the Cell & Gene Meeting on the Mesa 2021. Read More